New hope for breast cancer patients who stopped responding to standard treatment
NCT ID NCT07214662
Summary
This early-stage trial is testing a new drug called GDC-0587, both alone and combined with another cancer drug called giredestrant. It's for people with advanced ER-positive, HER2-negative breast cancer that has continued to grow despite previous treatment with CDK4/6 inhibitor drugs. The study aims to find safe doses and see how well these treatments work for 136 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cheng Kung University Hospital
RECRUITINGTainan, 70403, Taiwan
-
START - Midwest - EDOS
RECRUITINGGrand Rapids, Michigan, 49546-7062, United States
-
START - San Antonio - EDOS
RECRUITINGSan Antonio, Texas, 78229-3307, United States
Conditions
Explore the condition pages connected to this study.